Direxion Moonshot Innovators ETF (MOON)
- Previous Close
8.99 - Open
9.34 - Bid 8.99 x 3100
- Ask 9.56 x 3100
- Day's Range
9.08 - 9.17 - 52 Week Range
8.57 - 14.95 - Volume
26,739 - Avg. Volume
19,082 - Net Assets 25.55M
- NAV 9.22
- PE Ratio (TTM) --
- Yield 1.80%
- YTD Daily Total Return -18.64%
- Beta (5Y Monthly) 1.53
- Expense Ratio (net) 0.65%
The fund, under normal circumstances, invests at least 80% of its net assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index measures the performance of the securities of 50 U.S. companies that pursue innovative technologies that have the potential to disrupt existing technologies and/or industries (i.e., moonshot innovators). The fund is non-diversified.
Direxion Funds
Fund Family
Technology
Fund Category
25.55M
Net Assets
2020-11-11
Inception Date
Performance Overview: MOON
Trailing returns as of 4/23/2024. Category is Technology.
People Also Watch
Holdings: MOON
Top 10 Holdings (36.75% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MOON
PENN: Raising target price to $14.00
PENN ENTERTAINMENT INC has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetIRDM: Raising target price to $30.00
IRIDIUM COMMUNICATIONS INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target